Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ADC Therapeutics SA
< Previous
1
2
3
Next >
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
August 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
August 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
July 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
July 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
June 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
June 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 15, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
May 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
April 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
April 03, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
April 01, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
March 13, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
March 06, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Provides Business Updates
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Tickers
ADCT
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.